Erratum: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial (PLoS Comput Biol (2015) 11:2 (e1003973) DOI: 10.1371/journal.pcbi.1003973);Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial

PLoS Computational Biology

Volumn 11, Issue 2, 2015, Pages

  Edlefsen, Paul T ^a   Rolland, Morgane ^b   Hertz, Tomer ^a,c   Tovanabutra, Sodsai ^b   Gartland, Andrew J ^a   deCamp, Allan C ^a   Magaret, Craig A ^a   Ahmed, Hasan ^a   Gottardo, Raphael ^a   Juraska, Michal ^a   McCoy, Connor ^a   Larsen, Brendan B ^d   Sanders Buell, Eric ^b   Carrico, Chris ^e,f   Menis, Sergey ^e,f   Bose, Meera ^b   Arroyo, Miguel A ^g   O’Connell, Robert J ^g   Nitayaphan, Sorachai ^g   Pitisuttithum, Punnee ^h   Kaewkungwal, Jaranit ^g   Rerks Ngarm, Supachai ⁱ   Robb, Merlin L ^b   Kirys, Tatsiana ^j   Georgiev, Ivelin S ^j   Kwong, Peter D ^j   Scheffler, Konrad ^k   Pond, Sergei L Kosakovsky ^k   Carlson, Jonathan M ^l   Michael, Nelson L ^b   Schief, William R ^e,f,m   Mullins, James I ^d   Kim, Jerome H ^b   Gilbert, Peter B ^a   Howell, Shana ^b   Bates, Adam ^b   Lazzaro, Michelle ^b   O’Sullivan, Annemarie ^b   Lei, Esther ^b   Bradfield, Andrea ^b   Ibitamuno, Grace ^b   Assawadarachai, Vatcharain ^g   Chen, Lennie ^d   Konopa, Philip ^d   Nariya, Snehal ^d   Stoddard, Julia N ^d   Wong, Kim ^d   Zhao, Hong ^d   Deng, Wenjie ^d   Maust, Brandon S ^d   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b US Military HIV Research Program   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ MINISTRY OF PUBLIC HEALTH   (Thailand)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^l MICROSOFT RESEARCH   (United States)

^m MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; BINDING SITES; GENES; RISK PERCEPTION; VIRUSES;

ACID SITE; AMINO-ACIDS; ANTIBODY RECOGNITION; CLINICAL TRIAL; HOTSPOTS; IMMUNE RESPONSE; PLACEBO GROUPS; SIEVE ANALYSIS; SIGNATURE SITES; VACCINE EFFICACIES;

VACCINES;

CD4 ANTIBODY; GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MOLECULAR PHYLOGENY; PHYSICAL CHEMISTRY; PROTEIN GLYCOSYLATION; THAI (PEOPLE); VACCINATION; VIRUS GENOME; VIRUS IDENTIFICATION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONTROLLED STUDY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOLECULAR GENETICS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; BINDING SITES; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN;

EID: 84995610492     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/JOURNAL.PCBI.1004733     Document Type: Erratum

References (58)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220. doi: 10.1056/NEJMoa0908492 19843557
2. Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z, (1998) Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16: 1803–1811. doi: 10.1016/S0264-410X(98)00182-0 9795384
3. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275–1286. doi: 10.1056/NEJMoa1113425 22475592
4. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, et al. (2014) Vaccine-induced Env V1–V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6: 228ra239. doi: 10.1126/scitranslmed.3007730 24648342
5. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, et al. (2014) Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 9: e87572. doi: 10.1371/journal.pone.0087572 24504509
6. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, et al. (2013) Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 8: e75665. doi: 10.1371/journal.pone.0075665 24086607
7. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417–420. doi: 10.1038/nature11519 22960785
8. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 17: 366–371. doi: 10.1038/nm.2316 21358627
9. Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, et al. (2012) MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 7: e43396. doi: 10.1371/journal.pone.0043396 22952672
10. Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, et al. (2014) Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol 88: 8242–8255. doi: 10.1128/JVI.01164-14 24829343
11. Zolla-Pazner S, Williams C, Rolland M, Edlefsen PT, Gilbert PB, et al. (2014) IgG V3-specific antibody (Ab) reactivity in plasma from RV144: Implications for vaccine efficacy. Keystone Symposia: HIV Vaccines: Adaptive Immunity and Beyond (X3). Banff, Alberta, Canada.
12. Leitner T, Korber B, Daniels M, Calef C, Foley B, (2005) HIV-1 subtype and circulating recombinant form (CRF) reference sequences. HIV Sequence Compendium 2005: 41–48.
13. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289–300.
14. Lunn M, McNeil D, (1995) Applying Cox regression to competing risks. Biometrics 51: 524–532. doi: 10.2307/2532940 7662841
15. Gilbert PB, (2000) Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. Stat Med 19: 3065–3086. doi: 10.1002/1097-0258(20001130)19:22<3065::AID-SIM600>3.0.CO;2-D 11113943
16. Nickle DC, Heath L, Jensen MA, Gilbert PB, Mullins JI, et al. (2007) HIV-specific probabilistic models of protein evolution. PLoS One 2: e503. doi: 10.1371/journal.pone.0000503 17551583
17. Gilbert PB, Wu C, Jobes DV, (2008) Genome scanning tests for comparing amino acid sequences between groups. Biometrics 64: 198–207. doi: 10.1111/j.1541-0420.2007.00845.x 17608781
18. Edlefsen PT (2014) Evaluating the dependence of a non-leaky intervention’s partial efficacy on a categorical mark. arXiv:12066701v2.
19. Sun Y, Gilbert PB, (2012) Estimation of stratified mark-specific proportional hazards models with missing marks. Scand Stat Theory Appl 39: 34–52. 23519918
20. Gilbert PB, Sun Y (2014) Testing for vaccine efficacy against a spectrum of pathogen sequences in stratified mark-specific proportional hazards models with missing marks, with application to the RV144 HIV vaccine efficacy trial. Journal of the Royal Statistical Society, Series C, in press.
21. Taylor WR, (1986) The classification of amino acid conservation. J Theor Biol 119: 205–218. doi: 10.1016/S0022-5193(86)80075-3 3461222
22. Hellberg S, Sjostrom M, Skagerberg B, Wold S, (1987) Peptide quantitative structure-activity relationships, a multivariate approach. J Med Chem 30: 1126–1135. doi: 10.1021/jm00390a003 3599020
23. Sandberg M, Eriksson L, Jonsson J, Sjostrom M, Wold S, (1998) New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem 41: 2481–2491. doi: 10.1021/jm9700575 9651153
24. Wold S, Jonsson J, Sjostrom M, Sandberg M, Rannar S, (1993) DNA and peptide sequences and chemical processes multivariately modeled by principal component analysis and partial least-squares projections to latent structures. Analytica Chimica Acta 277: 239–253.
25. Scheffler K, Kosakovsky SL PRIME. HyPhy Wiki, http://hyphyorg/w/indexphp/PRIME.
26. Conant GC, Wagner GP, Stadler PF, (2007) Modeling amino acid substitution patterns in orthologous and paralogous genes. Mol Phylogenet Evol 42: 298–307. doi: 10.1016/j.ympev.2006.07.006 16942891
27. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477–1483. doi: 10.1126/science.1245625 24179159
28. Jojic N, Reyes-Gomez M, Heckerman D, Kadie C, Schueler-Furman O, (2006) Learning MHC I—peptide binding. Bioinformatics 22: e227–235. doi: 10.1093/bioinformatics/btl255 16873476
29. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, et al. (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2: e796. doi: 10.1371/journal.pone.0000796 17726526
30. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert PB, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431–441. doi: 10.1093/infdis/jis367 22634875
31. Faith A, O’Hehir RE, Malkovsky M, Lamb JR, (1992) Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy. Immunology 76: 177–184. 1353060
32. Henikoff S, Henikoff JG, (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89: 10915–10919. doi: 10.1073/pnas.89.22.10915 1438297
33. Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, et al. (2006) High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial. AIDS Res Hum Retroviruses 22: 1014–1021. doi: 10.1089/aid.2006.22.1014 17067272
34. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14: 1229–1246. doi: 10.1093/glycob/cwh106 15175256
35. Follmann D, Proschan M, Leifer E, (2003) Multiple outputation: inference for complex clustered data by averaging analyses from independent data. Biometrics 59: 420–429. doi: 10.1111/1541-0420.00049 12926727
36. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, et al. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176–186. doi: 10.1016/j.immuni.2012.11.011 23313589
37. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R, (2002) Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 76: 3852–3864. doi: 10.1128/JVI.76.8.3852-3864.2002 11907225
38. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, et al. (2006) Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 80: 750–758. doi: 10.1128/JVI.80.2.750-758.2006 16378977
39. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: 1688–1692. doi: 10.1038/nm.2985 23086475
40. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, et al. (2010) Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol 6: e1000955. doi: 10.1371/journal.pcbi.1000955 20949103
41. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166–5176. doi: 10.4049/jimmunol.1102756 22529301
42. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, et al. (2004) Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190: 702–706. doi: 10.1086/422258 15272397
43. Allen TM, O’Connor DH, Jing P, Dzuris JL, Mothe BR, et al. (2000) Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407: 386–390. doi: 10.1038/35030124 11014195
44. Council of the Global HIVVE (2010) The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 16: 981–989. doi: 10.1038/nm0910-981 20823883
45. Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, et al. (2011) HIV-1 vaccines and adaptive trial designs. Sci Transl Med 3: 79ps13. doi: 10.1126/scitranslmed.3001863 21508308
46. Gilbert PB, Self SG, Ashby MA, (1998) Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 54: 799–814. doi: 10.2307/2533835 9750238
47. Tamura K, Nei M, (1993) Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10: 512–526. 8336541
48. Guindon S, Gascuel O, (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696–704. doi: 10.1080/10635150390235520 14530136
49. Deng W, Maust BS, Nickle DC, Learn GH, Liu Y, et al. (2010) DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques 48: 405–408. doi: 10.2144/000113370 20569214
50. R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
51. Routledge RD, (1994) Practicing safe statistics with the mid-p. Canadian Journal of Statistics 22: 103–110.
52. Prentice RL, Kalbfleisch JD, Peterson AV, Jr.Flournoy N, Farewell VT, et al. (1978) The analysis of failure times in the presence of competing risks. Biometrics 34: 541–554. doi: 10.2307/2530374 373811
53. Imholte GC, Sauteraud R, Korber B, Bailer RT, Turk ET, et al. (2013) A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. J Immunol Methods 395: 1–13. doi: 10.1016/j.jim.2013.06.001 23770318
54. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307–312. doi: 10.1038/nature01470 12646921
55. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598. doi: 10.1371/journal.ppat.1000598 19763271
56. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, et al. (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85: 11502–11519. doi: 10.1128/JVI.05363-11 21849452
57. Nielsen M, Lund O, Buus S, Lundegaard C, (2010) MHC class II epitope predictive algorithms. Immunology 130: 319–328. doi: 10.1111/j.1365-2567.2010.03268.x 20408898
58. Gilbert PB, Novitsky V, Essex M, (2005) Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res Hum Retroviruses 21: 1016–1030. doi: 10.1089/aid.2005.21.1016 16379605